ESR1 and breast carcinoma: The combination of LUT and I3C selectively targets ER+ breast cancer cell MCF7 and T47D, but not TNBC cell lines BT-549 and MDA-MB-231 (Figure 1D), implicating that the synergistic inhibitory effects of the combination are mediated by the ERα signaling pathway.